Futu Holdings Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Futu Holdings Ltd trades at $105.5 (market cap $14.74B), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: Futu Holdings Ltd pays a 2.47% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Futu Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| FUTU | XBI | |
|---|---|---|
Market Cap | $14.74B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $199.04 | $164.28 |
52-Week Low | $89.76 | $86.92 |
Enterprise Value | $14.59B | — |
Dividend Yield | 2.47% | — |
Signals from Pluang's Aura AI — not financial advice
Futu Holdings Limited (FUTU) trades at $108.70, showing modest daily movement with a slight decline of 0.29%. The stock exhibits a bullish technical trend, supported by moving averages, while recent earnings have been mixed with two misses and one beat against expectations. Strong revenue growth and profitability margins highlight solid fundamental performance, though the company faces significant legal and regulatory scrutiny.
The outlook for FUTU is cautiously optimistic, driven by robust financial health and analyst support, but overshadowed by ongoing securities class action lawsuits alleging regulatory compliance failures. Key risks include legal liabilities and market sentiment pressure, while opportunities lie in sustained earnings growth and favorable valuation metrics.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Trailing returns across standard periods
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →